Stockscreener 앱 받기
2.62
1.50%
-0.04
시장 영업 전:
2.71
0.09
+3.44%
전일 마감가:
$2.66
열려 있는:
$2.75
하루 거래량:
505.78K
Relative Volume:
0.54
시가총액:
$177.08M
수익:
$6.96M
순이익/손실:
$-46.51M
주가수익비율:
-15.27
EPS:
-0.1716
순현금흐름:
$-37.99M
1주 성능:
-2.96%
1개월 성능:
-15.76%
6개월 성능:
-82.65%
1년 성능:
-76.61%
1일 변동 폭
$2.61
$2.805
1주일 범위
$2.42
$2.82
52주 변동 폭
$2.345
$19.05
Perspective Therapeutics Inc Stock (CATX) Company Profile
명칭
Perspective Therapeutics Inc
전화
509-375-1202
주소
350 Hills Street, Suite 106, Richland
CATX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
2.62 | 177.08M | 6.96M | -46.51M | -37.99M | -0.1716 |
|
ABT
Abbott Laboratories
|
129.89 | 225.27B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.37 | 140.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
363.66 | 138.77B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
92.33 | 118.39B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
67.95 | 39.95B | 5.72B | 4.17B | 259.90M | 6.97 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-11-25 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-01 | 개시 | Wedbush | Outperform |
| 2024-09-25 | 개시 | Truist | Buy |
| 2024-07-25 | 개시 | BofA Securities | Buy |
| 2024-05-09 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
Perspective Therapeutics Inc 주식(CATX)의 최신 뉴스
Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst - Benzinga
Brokers Set Expectations for CATX FY2024 Earnings - Defense World
Perspective Therapeutics at Barclays Healthcare: Radiopharmaceutical Innovations By Investing.com - Investing.com Canada
Brookline Initiates Perspective Therapeutics at Buy With $11 Price Target -March 10, 2025 at 08:33 am EDT - Marketscreener.com
Rhumbline Advisers Has $303,000 Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Given Average Rating of “Buy” by Brokerages - Defense World
Perspective Therapeutics (NYSE:CATX) Research Coverage Started at Scotiabank - Defense World
Perspective Therapeutics (NYSE:CATX) Upgraded at Lifesci Capital - Defense World
Scotiabank Initiates Coverage of Perspective Therapeutics (CATX) with Sector Outperform Recommendation - Nasdaq
Scotiabank starts Perspective Therapeutics with Sector Outperform By Investing.com - Investing.com South Africa
Scotiabank starts Perspective Therapeutics with Sector Outperform - Investing.com
Analysts Set Expectations for CATX FY2024 Earnings - Defense World
Promising Outlook for Perspective Therapeutics: Buy Rating Backed by Positive Trial Data and Market Positioning - TipRanks
Y Intercept Hong Kong Ltd Invests $33,000 in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics (NYSE:CATX) Raised to Strong-Buy at Cantor Fitzgerald - Defense World
CATX stock touches 52-week low at $2.35 amid market shifts - Investing.com
CATX stock touches 52-week low at $2.35 amid market shifts By Investing.com - Investing.com South Africa
BofA Securities gives a Neutral recommendation for Perspective Therapeutics Inc (CATX) - Knox Daily
Perspective Therapeutics Inc (AMEX: CATX) Posted -69.11% Loss This Year: What’s Next? - Stocks Register
LNTH: 2025 Guidance Provided - Yahoo Finance
Perspective Therapeutics to Present at Upcoming March Investor Conferences - The Manila Times
Radiopharmaceutical Developer CATX Secures Speaking Slots at TD Cowen and Barclays Healthcare Conferences - StockTitan
CATX stock touches 52-week low at $2.6 amid market fluctuations - Investing.com Australia
Vontobel Holding Ltd. Invests $51,000 in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics (CATX) Stock Price, News & Analysis - MarketBeat
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results - The Manila Times
Perspective Therapeutics, Inc. to Report Full Year 2024 Financial Results and Business Update on March 26, 2025 - Nasdaq
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results - GlobeNewswire Inc.
Allspring Global Investments Holdings LLC Has $10.60 Million Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Perspective Therapeutics (NYSE:CATX) vs. Titan Medical (NASDAQ:TMDIF) Head to Head Analysis - Defense World
SG Americas Securities LLC Has $83,000 Holdings in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Recommendation of “Buy” from Analysts - Defense World
Examining the Potential Price Growth of Perspective Therapeutics Inc (CATX) - Knox Daily
Cantor Fitzgerald Estimates CATX FY2024 Earnings - MarketBeat
Ratios Uncovered: Breaking Down Perspective Therapeutics Inc (CATX)’s Trailing Twelve Months Metrics - The Dwinnex
Perspective Therapeutics (NYSE:CATX) Upgraded at Cantor Fitzgerald - MarketBeat
Cantor Fitzgerald Predicts CATX FY2024 Earnings - Defense World
Amicus Therapeutics Inc Inc. (FOLD) Price Performance: A Technical Analysis Perspective - The InvestChronicle
The radiopharma landscape takes shape in neuroendocrine tumors - BioCentury
Perspective Therapeutics (NYSE:CATX) Stock Rating Upgraded by Cantor Fitzgerald - Defense World
Its Stock Has Paid Off Big Time For Perspective Therapeutics Inc - SETE News
CATX overperforms with a 1.52 increase in share price - US Post News
ForexTV | Small Business Resources - ForexTV.com
Perspective Therapeutics to Participate in Upcoming February Investor Conferences - The Manila Times
Precision Oncology Pioneer Perspective Therapeutics Takes Center Stage at Oppenheimer and B. Riley Conferences - StockTitan
Analysts review Perspective Therapeutics Inc’s rating - Knox Daily
Achilles Therapeutics Plc ADR Inc. (ACHL) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Analyzing Endeavor Group Holdings Inc (EDR) After Recent Trading Activity - Knox Daily
JPMorgan Chase & Co. Has $333,000 Stake in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
New Guidance for Amyloid and Tau PET Imaging Released - Imaging Technology News
JNM Publishes Guideline for FAP PET - Imaging Technology News
Perspective Therapeutics Inc (CATX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.40%
0.89%
자본화:
|
볼륨(24시간):